IPP Bureau
Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
By IPP Bureau - May 28, 2025
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification
By IPP Bureau - May 28, 2025
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
By IPP Bureau - May 27, 2025
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Zydus Lifesciences’ ‘breast cancer awareness campaign reaches millions
By IPP Bureau - May 27, 2025
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr
By IPP Bureau - May 27, 2025
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums reports Q4 FY25 with 12.4% revenue growth
By IPP Bureau - May 27, 2025
Akums invested Rs. 272 crore in capital expenditure during FY25
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
By IPP Bureau - May 26, 2025
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
By IPP Bureau - May 26, 2025
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
By IPP Bureau - May 26, 2025
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
By IPP Bureau - May 26, 2025
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Divi's Laboratories inks manufacturing and supply agreement with global pharma company
By IPP Bureau - May 26, 2025
The company expects meaningful revenue contribution from this long-term agreement
Lupin and SteinCares ink agreement for Ranibizumab in Latin America
By IPP Bureau - May 26, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
By IPP Bureau - May 24, 2025
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma to raise stake in US-based Pharmazz to 22.7%
By IPP Bureau - May 24, 2025
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
